Search

everythinglearnresearchcommunity

for

Search:↓

User found hair loss stabilization without side effects using a topical solution of 0.008% Finasteride, 2% RU, and Stemoxydine. Other treatments like Eucapil, Fluridil, RU-monotherapy, and Pyrilutamide didn't work for them.

Rosemary Oil may inhibit the activity of 5α-Reductase, potentially promoting hair growth. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.

The conversation provides a guide on using finasteride for hair loss, suggesting to start with a quarter of a 1mg pill daily after ensuring estradiol levels are within a specific range, and potentially increasing the dose if no side effects occur. It also recommends supplements like DIM, Calcium d-glucarate, and Zinc to manage high estradiol levels and side effects from finasteride.

The user is considering topical Saw Palmetto or Pumpkin Seed Oil due to sensitivity to finasteride and cost issues. They also use dermastamping for Minoxidil absorption and seek advice on timing to avoid systemic absorption.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

Oral DHT blockers like finasteride are preferred for their ease of use, effectiveness, and long-term safety data, while topical treatments like RU58841 lack extensive safety data and can be more cumbersome to apply. Oral treatments are generally considered more effective and convenient despite potential side effects.

The user is considering lowering the dosage of finasteride and minoxidil due to side effects like mood changes, lower libido, and brain fog, while wanting to maintain hair regrowth. A suggestion was made to try a lower dose of finasteride, such as 0.2 mg.

Curcumin, found in turmeric, may reduce DHT levels and hair loss, similar to finasteride, but without its side effects. However, natural DHT blockers are generally considered too weak to make a significant difference in hair loss.

The user diagnosed with DUPA tried treatments like dutasteride, finasteride, RU58841, and minoxidil without success and is considering a hair system. They hope for a future cure, possibly with PP405, and others suggest options like scalp biopsy and SMP.

A user is trying to reverse male pattern baldness (MPB) naturally by taking high doses of Vitamin D, improving diet, exercising, reducing stress, and other lifestyle changes, but plans to use finasteride if no results are seen in 60 days. Other users are skeptical, advising medical treatments like finasteride and warning against potential vitamin D overdose and the ineffectiveness of natural remedies for genetic hair loss.

People have reported hair thickening with Pyrilutamide, particularly using a 1% concentration. Some users are curious about the availability of different concentrations like 0.9%.

New hair loss treatments like GT20029 and PP405 could potentially replace minoxidil and finasteride, offering better results with fewer side effects. However, current treatments like finasteride and minoxidil are still effective for many, despite concerns about side effects.

The conversation discusses why there are no FDA-approved NSAAs like RU58841 on the market, despite their potential superiority to 5AR inhibitors like finasteride. It explores the effectiveness of treatments like Minoxidil, finasteride, and RU58841 for hair loss.

PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.

The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.

Cutting a 5 mg finasteride tablet into five equal parts and taking one piece daily is recommended for consistent dosing. This approach provides more stable DHT suppression than taking a full 5 mg tablet every five days.

A 28-year-old experienced hair loss and found success with daily 1mg Finasteride, noticing thicker hair without side effects. Despite this, their dermatologist suggested switching to expensive peptide serums, prompting the individual to seek a second opinion on long-term Finasteride and oral Minoxidil use.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

Finasteride and dutasteride may not significantly impact meibomian gland function since these glands do not rely on DHT. Some users report dry eyes and other side effects from finasteride, but these may be influenced by other factors or medications.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

The user experienced side effects from finasteride and is considering switching to dutasteride, while also using pyrilutamide to protect hair follicles. They are seeking advice on whether to add RU58841 to their regimen.

The user is considering stopping finasteride due to depression, anxiety, and difficulty building muscle, despite its effectiveness in stopping hair loss. Suggestions include reducing the dose, switching to topical solutions, or consulting a doctor for alternatives like dutasteride or RU58841.

A user with mild psoriasis on the scalp is using finasteride, topical minoxidil, and dermarolling for hair loss but plans to stop minoxidil on the crown due to psoriasis aggravation. Suggestions include switching to a lipid-based minoxidil, using Ketoconazole shampoo, or trying oral minoxidil.

Combining finasteride with dutasteride may have additive benefits for reducing scalp DHT, but the extent is unknown. Some users report less shedding when using both treatments, with variations in dosage and application methods.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

A 28-year-old male using only oral finasteride 1mg since May 15, 2024, reports no side effects and significant hair improvement. He plans to continue finasteride for three more months and is considering adding D3+K2 drops, zinc, folate, and magnesium glycinate.

A user wants to make a solution for RU58841 and finasteride powder using only glycerin and asks if ethanol is necessary. They are seeking advice on whether glycerin alone is sufficient.

People are discussing the potential benefits and drawbacks of a new time-release oral minoxidil (VDPHL01) for hair loss, with considerations about its cost, efficacy, and side effects compared to current treatments like 2.5mg doses and topical applications. Some users express interest in trying it if it proves effective and affordable, while others are cautious due to potential side effects or are satisfied with their current regimen.

Blocking DHT is not a cure for hair loss; instead, altering how scalp follicles respond to DHT might be more effective. Current treatments like topical finasteride and minoxidil are temporary solutions, and future approaches may involve gene therapy and bioengineering to change follicle behavior.

France is considering reviewing finasteride and dutasteride due to concerns about their safety, but a ban in the EU is unlikely due to regulatory hurdles. Many users express frustration over the potential ban, emphasizing the effectiveness of finasteride for hair loss and criticizing the influence of anecdotal evidence on public health policy.